| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.77▼ | 4.55▲ | 4.43▲ | 4.16▲ | 3.31▲ |
| MA10 | 4.53▲ | 4.15▲ | 4.10▲ | 3.25▲ | 3.88▲ |
| MA20 | 4.18▲ | 4.33▲ | 4.31▲ | 3.20▲ | 5.96▼ |
| MA50 | 4.44▲ | 3.65▲ | 3.28▲ | 4.03▲ | 12.37▼ |
| MA100 | 4.20▲ | 3.19▲ | 3.35▲ | 6.21▼ | N/A |
| MA200 | 3.39▲ | 3.49▲ | 4.05▲ | 12.66▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.107▲ | 0.039▲ | 0.006▲ | 0.313▲ | -0.018▼ |
| RSI | 63.837▲ | 63.973▲ | 66.381▲ | 61.857▲ | 41.940▼ |
| STOCH | 94.151▲ | 87.324▲ | 61.320 | 62.223 | 13.493▼ |
| WILL %R | -9.746▲ | -9.055▲ | -13.483▲ | -24.579▲ | -71.338 |
| CCI | 92.298 | 132.423▲ | 89.062 | 125.387▲ | -32.162 |
|
Friday, March 27, 2026 05:25 AM
Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in ...
|
|
Thursday, March 26, 2026 05:56 AM
Highlights advancement of first-in-class neuroprotective candidate targeting demyelinationTORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/03/26 | 3.71 | 4.9799 | 3.51 | 4.77 | 423,451 |
| 26/03/26 | 4.20 | 4.4066 | 3.60 | 3.83 | 277,853 |
| 25/03/26 | 4.77 | 5.6499 | 4.21 | 4.35 | 1,153,863 |
| 24/03/26 | 3.05 | 4.83 | 3.012 | 4.73 | 2,743,208 |
| 23/03/26 | 2.21 | 3.3499 | 2.18 | 3.10 | 1,381,092 |
| 20/03/26 | 2.32 | 2.3799 | 2.20 | 2.24 | 72,765 |
| 19/03/26 | 2.31 | 2.40 | 2.31 | 2.36 | 40,818 |
| 18/03/26 | 2.37 | 2.46 | 2.33 | 2.40 | 72,300 |
| 17/03/26 | 2.41 | 2.415 | 2.28 | 2.395 | 77,400 |
| 16/03/26 | 2.47 | 2.47 | 2.32 | 2.36 | 171,540 |
|
|
||||
|
|
||||
|
|